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Many cancer patients will develop spinal metastases. Local control is important for preventing neurologic
compromise and to relieve pain. Stereotactic body radiotherapy or spinal radiosurgery is a new radiation therapy
technique for spinal metastasis that can deliver a high dose of radiation to a tumor while minimizing the
radiation delivered to healthy, neighboring tissues. This treatment is based on intensity-modulated radiotherapy,
image guidance and rigid immobilization. Spinal radiosurgery is an increasingly utilized treatment method that
improves local control and pain relief after delivering ablative doses of radiation. Here, we present a review
highlighting the use of spinal radiosurgery for the treatment of metastatic tumors of the spine. The data used in
the review were collected from both published studies and ongoing trials. We found that spinal radiosurgery is
safe and provides excellent tumor control (up to 94% local control) and pain relief (up to 96%), independent of
histology. Extensive data regarding clinical outcomes are available; however, this information has primarily been
generated from retrospective and nonrandomized prospective series. Currently, two randomized trials are
enrolling patients to study clinical applications of fractionation schedules spinal Radiosurgery. Additionally, a
phase I clinical trial is being conducted to assess the safety of concurrent stereotactic body radiotherapy and
ipilimumab for spinal metastases. Clinical trials to refine clinical indications and dose fractionation are ongoing.
The concomitant use of targeted agents may produce better outcomes in the future.
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’ INTRODUCTION
The spine is the most common site of bony metastatic
disease. At least 40% of patients with advanced cancer will
have spinal involvement during the course of their disease
and approximately 5-10% of these patients will develop
some type of epidural cord compression. More than 90% of
metastatic lesions involving the spine are extradural;
intradural and intramedullary lesions represent o5% and
o1% of lesions, respectively (1-3).
Up to 50% of metastatic lesions originate from breast, lung
or prostate cancers. With improved systemic treatment and
augmented survival times, a greater number of patients with
other tumor histologies will develop secondary lesions (1).
Early diagnosis of spinal metastatic disease is critical because
functional outcomes depend on neurologic condition at the
time of presentation. Tumor-related pain typically appears early
in the morning or at night, generally improves with physical
activity and frequently precedes the development of other
neurological symptoms by weeks or months (4,5).
Uncontrolled spinal tumors typically produce pain and
diminish ambulatory ability and performance status. Treat-
ment is primarily palliative and is achieved by gaining local
control of the disease. In selected cases, chemotherapy or
surgery may pose as alternatives. The proper management of
patients with spinal metastasis requires multidisciplinary
treatment managed by orthopedic surgeons, neurosurgeons,
radiation oncologists, medical oncologists, pain medicine
specialists, radiologists and palliative care professionals.DOI: 10.6061/clinics/2016(02)09
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Although palliative radiotherapy plays a prominent role in
treating patients with metastatic spine disease, there is
increasing literature that supports the use of stereotactic
body radiotherapy (SBRT) or spine radiosurgery (SR)-based
ablative treatment (6-8).
SR is a recently developed radiation therapy technique
that delivers high-dose radiation to a tumor while minimi-
zing the radiation delivered to healthy, neighboring tissues.
A treatment target is defined by high-resolution imaging,
which is also used for treatment planning and dose
calculation. Precise delineation of the spinal cord requires
registration if computer tomography (CT) images to the
T2-weighted magnetic resonance imaging (MRI) series, or a
CT myelogram. Treatment is delivered using a combination
of externally placed strict immobilization devices and
image-guided (IG) intensity-modulated radiation therapy
(IMRT) (9-10). The treatment course is reduced to only a few
sessions (generally up to 5), with total doses ranging from
12 to 30 Gy delivered in 1 to 5 fractions.
SR aims to improve existing rates of clinical response and
tumor control, reduce re-treatment rates for metastatic
lesions by increasing the biologic equivalent dose1, minimize
radiation doses to healthy organs and allow safer reirradia-
tion in previously treated sites (11). SR spares the spinal cord
better than conventional radiotherapy and fractionated
IMRT, even when very high doses are prescribed to an area
only a few millimeters in size. Immobilization devices and
image-guidance (IGRT) tools, such as kilovoltage cone-beam
imaging (12), have reduced treatment errors associated with
traditional radiotherapy and enabled safe and accurate
delivery of the highly conformal dose distributions produced
by IMRT techniques (13).
The aim of this article was to review published data on
and ongoing trials of SR for metastatic tumors of the spine.
Review Methodology
A literature search was conducted using the MEDLINE
database [via PubMed] and the Clinicaltrials.gov database
for all article types available through September 2014. No
other filter was activated and we assessed all of the
published data that were available in English. Controlled
vocabulary was leveraged as well as text words to develop
the search strategy detailed below.
Our search terms and strategy used the following MED-
LINE MeSH terms: ((Spinal Neoplasms [MeSH] OR Neo-
plasm, Spinal OR Neoplasms, Spinal OR Spinal Neoplasm
OR Spine [MeSH] Vertebral Column OR Column, Vertebral
OR Columns, Vertebral OR Vertebral Columns OR Spinal
Column OR Column, Spinal OR Columns, Spinal OR Spinal
Columns OR Vertebra OR Vertebrae) AND (Radiosurgery
[MeSH] OR Radiosurgeries OR Radiosurgery, Stereotactic
OR Radiosurgeries, Stereotactic OR Stereotactic Radiosur-
geries OR Stereotactic Radiosurgery OR Gamma Knife
Radiosurgery OR Gamma Knife Radiosurgeries OR Radio-
surgeries, Gamma Knife OR Radiosurgery, Gamma Knife OR
Stereotactic Body Radiotherapy OR Body Radiotherapies,
Stereotactic OR Body Radiotherapy, Stereotactic OR Radio-
therapies, Stereotactic Body OR Radiotherapy, Stereotactic
Body OR Stereotactic Body Radiotherapies OR CyberKnife
Radiosurgery OR CyberKnife Radiosurgeries OR Radio-
surgeries, CyberKnife OR Radiosurgery, CyberKnife OR
Radiosurgery, Linear Accelerator OR Linear Accelerator
Radiosurgeries OR Radiosurgeries, Linear Accelerator OR
Linear Accelerator Radiosurgery OR Radiosurgery, Linac OR
Radiosurgeries, Linac OR LINAC Radiosurgery OR Radio-
surgeries, LINAC)). For the Clinicaltrials.gov database, we
used the following search terms: Spinal Neoplasms OR Spine
AND Radiosurgery OR Radiation Therapy.
Two authors independently screened all identified studies
by title and abstract. Studies with the following inclusion
criteria were collected: primary focus on clinical outcome,
evaluation of feasibility, assessment of toxicity and presenta-
tion of technical aspects. Additional treatment with chemo-
therapy, targeted therapy, endocrine therapy and surgery
were permitted if radiotherapy was the primary intervention
under investigation. All references in each included study
were manually searched for important missed publications.
Re-reporting and clinical trials were manually removed, and
only the most recent publications were evaluated (14-16).
Studies that did not focus on SR were removed. Articles
published in languages other than English were excluded.
We also excluded articles with a main focus of epidemiology,
research design, diagnosis, basic science or clinical guide-
lines. Editorial commentaries were removed. Finally, we
removed studies with fewer than 20 patients, heterogeneous
treatment design (multiple levels of SR dose or SR not the
main objective of analysis) and less than 6 months of follow-
up. A third evaluator resolved any disagreements.
Review Results
We identified 663 studies [MEDLINE n=285; Clinicaltrials.
gov n=378]). After assessing and removing duplicated
records (n=10), 653 studies were screened; of these, only
155 met the eligibility criteria for full-text assessment. After
manually screening the full-text articles of the remaining
studies (n=155 [MEDLINE n=132; Clinicaltrials.gov n=23) for
our inclusion criteria, we identified 60 unique articles for
qualitative analysis (Figure 1).
Data Extraction
One investigator (F.Y.M.) independently extracted data
from all 60 studies. The following data were collected: study
design, year of publication, non-radiotherapy interventions
(e.g., hormone therapy, chemotherapy, targeted agents or
procedures), type of radiotherapy treatment course (IMRT,
IGRT, proton therapy, and brachytherapy), and primary
assessed outcome [overall survival (OS), local control, pain
control, quality of life measures and toxicity].
Technical Aspects of Spinal Radiosurgery
Dose Delivery Technique: Intensity-Modulated Radio-
therapy. The use of IMRT is required to deliver high-dose
radiation to vertebra while simultaneously sparing the spinal
cord and other adjacent critical organs (e.g., the esophagus or
brachial plexus). The development of IMRT was a major
improvement over 3D conformal radiotherapy (3DCRT) (17).
IMRT is capable of modulating a target-shaped field of
uniform radiation intensity into hundreds of pixel-like
‘‘beamlets’’, each with its own intensity. This advancement
allows the delivery of increased radiation intensity to areas
within the beam that are contained within the target volume
1The biological equivalent dose is a correlation of different radiotherapy dose schedules (total dose and fractionation) that produce similar biological effects.
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only and reduces the radiation delivered to healthy organs via
so-called intensity modulation. As a result, it is possible to
create complex dose distributions characterized by steep
dose gradients (i.e., significant dose differences over a short
distance) to create a target (e.g., vertebra) with a concave
shape to avoid hitting organs at risk (e.g., the spinal cord).
IMRT fields are often created through inverse planning
optimization algorithms, where doses are prescribed to
delineated volumes and potential plan alternatives are gener-
ated with guidance from a treatment planner (e.g., a dosimetrist
or medical physicist) until a reasonable solution is found.
Delivery via these intensity-modulated beams is achieved
through the use of physical compensators (which are outdated
technology) or, preferably, multi-leaf collimators (MLCs). An
MLC serves as an add-on to a conventional rectangular linear
accelerator’s collimator. MLCs consist of sets of opposed leaf
pairs (typically approximately 60 to 80 pairs of tungsten metal
bars) that automatically longitudinally displace in and out of a
beam’s rectangular aperture to produce irregular custom
shapes. Via the continuous or stepwise movement of the leaves
during radiation emission, it is possible to modulate the
intensity across a beam. This modulation of beam intensity
improves the therapeutic index by allowing for increased target
dose and reducing damage to normal tissues.
With the use of IMRT, a sharp dose gradient of approxi-
mately 10% per millimeter can be achieved near the spinal cord
(18). For example, in a photon-based IMRT plan, where the
spinal cord is 3 mm from the edge of the target volume, 18 Gy
can be delivered to more than 90% of the target volume, while
the maximum dose to the spinal cord surface would be less
than 14 Gy (Figure 2).
The rationale for using proton and other particle beams is
the ability to achieve excellent dose distribution at a tumor
target with virtually no exit dose delivered beyond the target
volume. The Bragg peak phenomenon associated with particle
beam radiation results in an extremely steep dose fall-off over a
course of a few millimeters (Figure 3). The advantage of this
characteristic lies primarily in the lack of exit dose beyond the
Bragg peak. However, there is currently no routine indication to
use proton radiation for SR.
Patient Setup: Immobilization and Image Guidance. The
general treatment parameters for SR are currently based on the
use of IMRT and, more recently, volumetric arc therapy (VMAT,
which is dosimetrically equivalent but more efficient and faster
than IMRT). In addition, SR requires the use of image guidance
and setup verification. The overall precision of different
components (e.g., mechanical aspects, image guidance and
beam targeting) should allow treatment accuracy within 1 mm
(19). The primary role of IGRT is to guide patient re-positioning
based on a target itself (in this case, the vertebral body being
treated). Secondly, depending on the IGRT technique, patient
position can be monitored during treatment to assure that the
target remains static through frequent intra-fraction imaging.
IGRT also requires that a patient remain immobilized in the
correct position throughout dose delivery; devices exist specifi-
cally for this purpose.
Figure 2 - Spine radiosurgery. Target definition (vertebral body),
radiotherapy isodose lines (upper right) and dose distribution
(below). The axial and sagittal views illustrate ‘‘dose-shaping’’
promoted by IMRT, with sparing of the spinal cord and
esophagus. [Male, 62 years old, metastatic melanoma of the
spine, stable lesion, ECOG 0, treated with SR via 18 Gy delivered
in a single fraction. The distance between the GTV (gross target
volume) and the medulla is approximately 2 mm].
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Figure 1 - Flow diagram.
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For SR, a patient is immobilized in a stereotactic body frame
or immobilization cradle. Such devices are noninvasive and thus
do not guarantee that a patient will remain perfectly positioned.
Nonetheless, based on pre- and post-treatment imaging findings,
an approximate 95% rate of immobilization accuracy has been
reported for the noninvasive devices that are currently in use
(20). Immobilization has emerged as an issue of great importance
because planning technology is ineffective unless a patient is
accurately positioned.
Accurate positioning is possible through patient coopera-
tion. After proper positioning is achieved, image acquisition,
ideally using onboard cone-beam imaging just before RT
treatment, can be initiated. Pretreatment images are registered
and compared with target images acquired during simulation
to identify and correct setup errors. Typically, these variations
are minimal and account for displacements of less than 3 milli-
meters from the ideal position. These displacements are
accounted for by repositioning the patient to match the target
before treatment begins. After corrections are made in each
direction, spine positioning can be considered truly reliable for
a treatment session, with less than 1 mm of error (21).
Clinical Assessment and Patient Selection. Due to the
improved OS gained by improving local and systemic
therapies and the capacity of SR to improve local tumor
control, SR has great potential for increased utilization. Spine
metastatic disease is often observed in radiation oncology
clinics and studies of SR have indicated that the technique
results in excellent local control rates (8,22,23). The indica-
tions for SR are still expanding; they currently include pain
related to an involved vertebral body, radiographic tumor
progression, lesions associated with progressive neurologic
deficits, adjuvant therapy after surgical intervention for
radioresistant metastasis and the need for reirradiation (8).
Memorial Sloan Kettering Cancer Center (MSKCC)
utilizes a multidisciplinary spine team to identify and treat
patients who would most benefit from SR. The MSKCC
Spine Clinic developed and now implements the algorithm
NOMS for metastatic spine disease. This algorithm incorpo-
rates assessments of (N)eurologic condition, (O)ncologic
status, (M)echanical instability and (S)ystemic disease (24).
The goal of this decision framework is to provide a rapid,
highly reliable assessment (e.g., low-grade extradural spinal
cord compression (ESCC) versus high-grade disease or
mechanical versus biologic pain) for the treatment of spinal
metastases. Such treatment integrates radiation therapy,
interventional neuroradiology and surgical approaches
(Table 1) (24,25).
Local Disease Control. Local control is defined as the
absence of recurrent cord compression within an irradiated
field or the absence of progression at a treatment site. The
local control achieved with SR has been assessed in many
series. Several of these series are highlighted below.
The Radiation Therapy Oncology Group (RTOG) pub-
lished a phase II study evaluating the use of SR for localized
spinal metastases (RTOG 0631). In this multicenter phase II
study, patients with 1-3 lesions and a numerical rating pain
scale score ofX5 were treated. A total of 44 patients received
16-18 Gy of single-fraction SR. Grade 1/2 and grade 3 SBRT-
related adverse events were observed in seven and zero
patients, respectively. The investigators concluded that SR is
safe and feasible in the multi-institutional setting (10).
Several departments have also published their experiences,
which are summarized in Table 2 (22,32,45,55-60).
For metastatic spinal tumors, SR has been postoperatively
utilized in several series and in cases of progression following
conventional fractionated palliative radiation treatment. Even
in these challenging settings, SR achieves local control in
approximately 85-94% of cases (22,23,26,18,27). When used as
a primary treatment, long-term radiographic tumor control
has been demonstrated in 90% of cases (22,28-30).
In an assessment of 103 consecutive spinal metastases in
93 patients without high-grade ESCC who were treated with
SBRT (median dose, 24 Gy delivered in a single fraction;
range, 18-24 Gy), MSKCC reported an overall local control
rate of 90% at a median follow-up of 15 months. There were
no deaths attributed to local failure. No patient experienced
myelopathy or radiculopathy, even when the maximum
spinal dose was raised to 14 Gy from 12 Gy (23).
In another phase I/II trial, 149 patients (166 metastatic
spine lesions) were treated with SR. None of the patients
showed evidence of mechanical instability or cord compres-
sion and 50% of them exhibited radioresistant tumor
histology. Each of the patients received a total dose of 27-30
Gy, typically delivered in three fractions. More than half of the
patients had been treated with one prior course of conven-
tional radiation therapy (30 Gy delivered in ten fractions). The
local tumor progression-free survival reported after SR was
81% at 1 year and 72% at 2 years. Adverse events were
Table 1 - Current NOMS decision framework for high-grade epidural spinal cord compression (ESCC) (Adapted from Laufer et al. (24)).
Neurologic Oncologic Mechanical Systemic Decision
High-grade ESCC ±
myelopathy
Radiosensitive Stable CRT
Unstable Stabilization followed
by CRT
Radioresistant Stable Able to tolerate surgery Decompression / stabilization
followed by SR
Radioresistant Stable Unable to tolerate surgery CRT
Radioresistant Unstable Able to tolerate surgery Decompression / stabilization
followed by SR
Radioresistant Unstable Unable to tolerate surgery Stabilization followed
by CRT
CRT: Conventional radiotherapy; SR: Spine radiosurgery.
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minimal and SR was associated with robust pain reduction
(26% of the patients were pain-free before SR and 54% were
pain-free 6 months after SR). SR also reduced pain medication
use and was associated with improved quality of life (31).
In another report, 88 patients with 120 spinal metastases
from pathologically proven high-grade sarcoma were treated
with hypofractionated [3-6 fractions; median dose, 28.5 Gy;
n=52 (43.3%)] or single-fraction SR [median dose, 24 Gy; n=68
(56.7%)]. At a median follow-up of 12.3 months, the
12-month local control rate was 87.9%, and the OS was 60%.
Single-fraction SR showed better local control than hypofrac-
tionation (p=0.007). The rate of adverse effects was low, and
no grade 43 toxicity was reported (32).
Pain Control. Despite the use of heterogeneous methods
for pain evaluation (e.g., verbal analysis scale and subjective
measurements of pain relief, among others), most series
report very high pain control rates (up to 96%) at 12 months
(8). Pain control rates were still high even in cases of
radioresistant tumors, such as melanoma, sarcoma, renal cell
tumors, non-small cell lung cancer, gastrointestinal tumors
and others (96% and 85% rates of pain control were achieved
for melanoma and renal cell carcinoma, respectively)
(8,30,33). SR has also been reported to provide better
pain control more rapidly than conventional radiotherapy,
with pain relief sometimes observed within 24 hours of
treatment (34).
It is thought that conventional radiation doses may be
sub-therapeutic for radioresistant tumors. A systematic
review of randomized controlled trials (RCTs) reported that
conventional radiotherapy can successfully palliate bone
pain in 50 to 80% of patients, but complete pain relief is only
achieved in up to 30% of patients (35-36). Thus, SR is feasible
Table 2 - Important clinical results following spine radiosurgery (based on recent prospective and retrospective data).
Author Study design SR indication N / Dose IGRT Reported results
Ahmed
et al. (55)
Prospective case
series
SM: primary and
reirradiation
66 patients
(85 lesions)
24 Gy (SF and HF)
BodyFix or thoracic-T double
vacuum
system*
ExacTrac X-ray system with a 6D
robotic
couch#
mOS (12 months): 52.2%
LC (1 year): 91.2%
No grade 4 toxicity
Amdur et
al. (56)
Prospective case
series
SM: primary and
reirradiation
21 patients
(12 reirradiation)
Dose: 15 Gy
Customized
body mold / onboard cone-beam CT
OS (12 months): 60%
43% pain relief
No grade 3 or 4 toxicity
Garg et
al. (57)
Prospective case
series
SM: primary SR 61 patients
(63 tumors)
16-24Gy (SF)
BodyFix / stereotactic localizer and
target frame
LC (18 months): 88%?
Supports SR as first-line treatment
Klish et
al. (58)
Prospective case
series
SM: reirradiation 58 patients
Dose: variable
BodyFix / stereotactic localizer and
target frame
LC (12 months): 89.3%
o 5% of isolated failures of the
nonirradiated adjacent vertebral
body = focal SR feasible
Garg et
al. (45)
Prospective case
series
SM: reirradiation 59 patients
(63 tumors)
30 Gy (5
fractions)
27 Gy (3
fractions)
BodyFix stereotactic body frame
system / stereotactic localizer and
target frame
OS (12 months): 76%
LC (12 months): 100%
Freedom from neurological
injury: 92%
Gerszten
et al. (22)
Prospective
nonrandomized
cohort study
SM: primary and
reirradiation
500 patients
12.5 - 25 Gy
(SF and HF)
CyberKnife: Aquaplast facemask$ LC: 90% of primary lesions
and 88% of lesions treated
for radiographic tumor progression
Clinical improvement (previous
neurologic deficit): 84%
Long-term pain improvement: 86%
Haley et
al. (59)
Prospective case
series
Efficacy and cost
effectiveness of CRT
versus SR
44 patients
(22 CRT and
22 SR)
Dose: variable
CyberKnife system Similar pain relief
No late complications in either
group
CRT: more acute toxicities and
was more likely to require
additional interventions
Folkert
et al. (32)
Retrospective
case series
SM: primary and
reirradiation
(sarcoma)
120 lesions
(SF and HF
24 Gy)
Noninvasive customized cradle /
onboard
imaging (orthogonal KV imaging
and
cone-beam CT)
OS 60%
LC (12 months) 87.9%
Low toxicity reported
Zelefsky
et al. (60)
Retrospective
case series
SM: primary and
reirradiation (renal
cell)
105 lesions
(SF and HF)
Dose: 24 Gy
Customized cradle / digitally
reconstructed radiographs from the
simulation studies for
each field’s beam’s eye view
PFS (36 months - HF): 17%
PFS (36 months -SF 24 Gy): 88%
SF: improve local control
Legend: N: number of patients; IGRT: image-guided radiotherapy; SF: single fraction; HF: hypofractionated; SM: spine metastasis; Hypo: hypofractionated;
LC: local control; OS: overall survival; PFS: progression-free survival; SR: spine radiosurgery; CRT: conventional radiotherapy; CT: computed tomography.
* (Medical Intelligence, Schwabmunchen, Germany);
#(Brainlab, Feldkirchen, Germany);
%(Integra- Radionics Burlington, MA);
$(Aquaplast Corp., Wyckoff, NJ).
105
CLINICS 2016;71(2):101-109 Spine Radiosurgery
Moraes FY et al.
for the treatment of spinal metastases and promotes high
rates of local control and pain relief with low rates of toxicity.
Postoperative Irradiation. It has been suggested that
patients with metastatic spinal cord compression (MSCC) will
benefit more from high-dose and/or SR radiotherapy than they
would from low-dose fractioned radiotherapy. Surgery is
fundamental the management of patients with symptomatic
MSCC or high-grade spine compression. Patchell et al. reported
in a RCT that surgical decompression is significantly beneficial.
A larger number of patients who underwent surgery plus
postoperative RT regained the ability to walk compared to those
who received only RT. Ambulatory status was also maintained
for longer in the surgery plus RT arm (37).
However, the exact criteria for surgery in cases of MSCC
remain controversial. The following factors are usually necessary
for improved outcomes: favorable PS and expected OS, a
relatively radioresistant tumor type and MSCC accompanied
with mechanical instability (24,25,38,39). Epidural disease is an
important limiting factor with respect to SR efficacy. Al-Omair et
al. reported that epidural disease progression is the most
common cause of treatment failure after SR and a significant
predictor of poor local control (40).
To more safely administer an ablative radiation dose, it
may be possible to perform separation surgery to create a
space of 2–3 mm between a metastatic lesion and the spinal
cord. This allows a full dose to be administered to the entire
tumor volume while minimizing the radiation dose delivered
to the spinal cord. The surgical procedure is performed using
epidural decompression and spinal stabilization without gross
total or en bloc tumor resection (41,42).
Recently, MSKCC has published their experiences with
186 patients treated from 2002 to 2011 who were managed with
separation surgery followed by SR (hypofractionated or single
fraction) (43,44). In this cohort, 136 patients exhibited high-
grade cord compression or MSCC and the full cohort received
spinal decompression surgery followed by SR within a median
of 48 days after surgery. Postoperative SR provided durable
local control, with a cumulative local progression incidence of
16.4% at 1 year (95% confidence interval: 10.7–22.2).
Thus, for patients presenting with spinal cord compres-
sion, separation surgery followed by SR is a safe and effective
treatment option. Integrative treatment (i.e., SR and separation
surgery) may reduce the extent of surgery and also provide
faster and more effective radiotherapy treatment.
Reirradiation of Spinal Metastases. SR is an indicated
treatment for cases requiring reirradiation of spinal levels and
may be associated with superior tumor control rates and pain
relief relative to conventional radiotherapy. However, care must
be taken when a reirradiation volume either contains or is very
close to the spinal cord, esophagus or other organs at risk. In the
reirradiation setting, SR provides a local control rate of 66-93%
and a low rate of toxicity when treatment constraints and quality
assurances are respected (45-47).
Complications. A pain flare or acute worsening of pain
has been found to occur in 20% of cases after SR. Such a flare
may occur within 24 hours of single-dose radiation or a few
days after the use of a hypofractionated scheme (48,49). The
pain is usually transient and can be managed with
corticosteroids or non-steroidal anti-inflammatory drugs.
Radiation-induced spinal cord injury can be a severe event,
but it is not often observed. The best method of preventing
myelopathy is avoidance of unnecessary radiation to the
spinal cord and adherence to planned dose constraints.
Vertebral fracture (VCF) is a common event after SR. VCF
has an incidence of approximately 20% and is associated with
higher doses per fraction (X20 Gy) and with 3 of the 6 original
Spinal Instability Neoplastic Score (SINS) (50) components,
including baseline VCF, a lytic tumor and spinal deformity
(51). Attention must be paid to identifying high-risk patients
who would benefit from prophylactic kyphoplasty.
Other events, such as risk of mucositis and skin dermatitis,
have also been associated with SR. Additionally, there are
many factors that may influence SR toxicity. Such factors
include tumor proximity to and extension in adjacent normal
tissues, concurrent systemic therapy and targeted therapy and
comorbidities (e.g., acute infection, prior surgery, diabetes,
collagen vascular disease, or any genetic predisposition).
Thus, in SR, end-to-end patient assessment, planning
and dosimetry are important for ensuring a safe treatment
procedure.
Future Perspectives: Randomized Data and Combination
Targeted Therapy. Multiple prospective and retrospective
series on SR have been reported. There are increasing expecta-
tions for randomized phase III trials, prospective phase II studies
and the use of molecularly targeted agents as a new approach to
treatment. Data from phase I, II and III trials are summarized in
Table 3 (9,52,53,61-74).
The RTOG is currently enrolling patients for a phase III trial,
which is estimated to include 380 patients. The anticipated
completion of primary data collection for this trial is July 2015 (9).
The trial compares 2 groups of patients: the first arm consists of
patients undergoing SR (16 Gy delivered in a single fraction),
while the second arm consists of patients undergoing conven-
tional external beam radiotherapy treatment (800 cGy delivered
in a single fraction). The patients will be stratified according to
number of spine metastases treated (1 vs. 2-3) and radioresistant
tumor classification (with radioresistant tumors including soft
tissue sarcomas, melanomas, and renal cell carcinomas). The
primary outcome is to determine whether SR improves pain
control (measured by the 11-point Numerical Rating Pain Scale
[NRPS]) compared with conventional external beam radio-
therapy. The following secondary outcomes are also included:
pain response and pain/lesion control at a treated site(s) com-
pared with conventional external beam radiotherapy, as mea-
sured by the NRPS; local control; adverse events measured by
NCI CTCAE v3.0 criteria; and long-term side effects (24 months)
of SR on vertebral bone (e.g., vertebral compression fractures)
and spinal cord, as measured by MRI.
MSKCC and collaborators are conducting a phase II RCT
with an estimated enrollment of 200 patients and a primary
anticipated completion date of October 2015. This trial includes
patients over 18 years in age with metastatic lesions in the bone,
spine, soft tissue and lymph nodes that have not been previously
irradiated. The patients will be randomized into 2 groups: the
first arm will receive SR using a single dose of 24 Gy and the
second arm will be treated with fractioned SR using 27 Gy
delivered in 3 fractions (30). The primary outcome is a
comparison of loco-regional control rates at 24 months. The
secondary outcomes are a toxicity comparison at 24 months,
determination of failure patterns between the two cohorts at
24 months, and SUVuptake as a measure of tumor response and
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changes in tumor perfusion evaluated by dynamic contrast-
enhanced (DCE)-MRI.
The Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins University is currently conducting a phase I study that
aims to assess the safety of prescribing either SR or stereotactic
brain radiosurgery (SRS) in combination with ipilimumab
(Bristol-Myers Squibb, New York, NY) to treat patients with
newly diagnosed brain or spinal metastases frommelanoma. The
estimated enrollment is 30 patients, with a primary completion
date of December 2016. The primary outcomes are a description
of the number and severity of adverse events at 24 months and
an assessment of the safety profile of SBRT with concurrent
ipilimumab. The secondary outcomes include estimates of local
control rates in the brain and spine at 24 months, determination
of the systemic control rate and evaluation of progression-free
survival (59). Recently published data have reported that using a
combination of ipilimumab plus SRS for melanoma brain
metastasis is well tolerated and associated with better loco-
regional control and possibly better survival rates. However,
there was a 20% rate of grade 3 or 4 toxicity using this treatment
modality (53).
A retrospective series evaluated 106 metastatic renal cell
carcinoma patients (55 spine and 51 brain metastases) who
were treated with simultaneous standard sorafenib or
sunitinib (anti-angiogenic therapy) and stereotactic radio-
surgery (SRS) or SR. The patients received an average dose
of 20 Gy per lesion (range, 19–20 Gy) (54). The study
showed no skin toxicity, neurotoxicity or myelopathy
augment the adverse effects of anti-angiogenic therapy.
Additionally, no treatment-related deaths or late complica-
tions were reported at 15 months. The local control rates for
cerebral lesions at 12 and 24 months were 100% and 96.6%,
respectively; for spinal lesions, the local control rates at
12 and 24 months were 94.1% and 90.4%, respectively. This
series demonstrated that the use of SR / SRS plus anti-
angiogenic therapy in this setting is safe and provides
excellent local control.
The use of SR for metastatic tumors of the spine is safe
and offers high local control rates. There are extensive data
regarding pain control and local control; however, these data
are mostly derived from retrospective and nonrandomized
prospective series. Further studies are needed to determine
appropriate SR fractionation schedules and clinical indica-
tions. Two RCTs (clinicaltrials.gov numbers NCT00922974
and NCT01223248) are ongoing and may provide the data
needed to gain better insight into the factors that constitute
optimal therapy. There is increasing interest in and a
subsequent need to characterize combination drug therapy
Table 3 - Spine radiosurgery. Interventions and primary outcome descriptions from clinical trials registered at clinicaltrials.gov.
Study / Date
started
Status Design Condition Intervention Primary outcomes
NCT01654068
(61) / Jul, 2012
Recruiting Phase II Spinal
metastasis
1) 2-3 SM: 14 Gy SF
2) 1 SM: 14 Gy SF
Any skeletal-related event
NCT01223248
(52) / Oct, 2012
Recruiting Phase III Spinal
metastasis
SR 24 Gy SF vs. SR, 27 Gy (HF) Loco-regional control rates
NCT01290562
(62) / Jun 2011
Recruiting Phase II Spinal
metastasis
20-24 Gy SF; or 20-24 Gy (HF)
No prior RT or prior RT or Post-op
Local control: image /
symptoms
NCT00573872
(63) / Dec 2007
Not recruiting
(active)
Phase I/II Spinal
metastasis
Phase 1: 20-25 Gy (HF) / Phase 2:
9-24 Gy (SF)
TT: Safety
NCT01849510
(64) / Apr 2013
Recruiting Phase II
(2 arms)
Spinal
metastasis
HF: 12 3 Gy+integrated boost
124 Gy / CRT 103 Gy
Local control
NCT02167633
(65) / Jul 2014
Recruiting Controlled (2
arms)
MSCC Decompression surgery plus
CRT / SR 16 Gy SF
Ambulatory status
NCT00853528
(66) / Feb 2009
Not recruiting
(active)
Phase I Spinal
metastasis
Maximum tolerated dose HF SR Dose escalation
NCT00631670
(67) / Feb 2008
Completed Controlled Spinal
metastasis
15 Gy SF / 252.8 Gy Safety
NCT01525745
(68) / Jan 2012
Completed Phase II Spinal
metastasis
SR HF / CRT 10 fractions Pain control: NPRS
NCT01826058
(69) / Apr 2013
Recruiting Phase II MSCC 16 -24 Gy SF / 21-36 HF Neurologic response
NCT01254903
(70) / Dec 2012
Recruiting Phase I MSCC 18 Gy SF Safety
NCT00922974 (9) /
Nov 2009
Recruiting Phase II:
completed
Phase III
Spinal
metastasis
SR 16 Gy SF / CRT 1 800 cGy Pain control
NCT01752036
(71) / Mar 2013
Recruiting Phase II Spinal
metastasis
SR: 30 Gy (HF) Safety
NCT01347307
(72) / Sep 2008
Not recruiting
(active)
Phase IV Spinal
metastasis
Benign: 12-16 Gy SF; 21-27 Gy HF
Metastases: 14-25 Gy SF; 21-30 Gy
HF
Tumor control
NCT01231061
(73) / Nov 2010
Completed Phase II Spinal
metastasis
Arm 1:
SR 24 Gy HF / SR 16 Gy SF
Pain control
NCT01950195
(53) / Jun 2013
Recruiting Phase I Spinal
metastasis
SR+ipilimumab Safety
NCT01624220
(74) / Jun 2012
Recruiting Assignment Spinal
metastasis
SR+4 gold seeds implanted Safety
SR: spine radiosurgery; NPRS: numeric pain rating scale; TT: tomotherapy; QA: quality assurance; SF: single fraction; HF: hypofractionated; CRT:
conventional radiotherapy; Post Op.: post operative; MSCC: metastatic spinal cord compression.
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with SR to enhance local control and even improve survival
in select groups of patients.
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